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Introduction
Inhibitors of bone resorption can preserve bone mass
and maintain normal bone architecture, thereby pre-
venting fractures in later life (1).
The bone-resorption process requires secretion of pro-
tons by the osteoclasts (2). This allows the dissolution of
the bone mineral and the maintenance of the acidic envi-
ronment required by proteolytic enzymes to degrade the
bone matrix (3). Protons are extruded by a proton pump
belonging to the class of vacuolar-type H+-ATPases (V-H+-
ATPases (4) that is present in high concentration on the
ruffled border (apical surface) of the resorbing osteoclast.
The osteoclast V-H+-ATPase therefore represents a
previously unexploited molecular target for the design
of novel agents for reducing osteoclast activity. How-
ever, since V-H+-ATPase is an ubiquitous component of
eukaryotic organisms and is the major electrogenic
pump of endomembranes (5), the selective inhibition
of the osteoclast V-H+-ATPase must be achieved in
order to afford novel drugs that may constitute useful
and safe agents for the treatment of osteoporosis and
related osteopenic diseases.
Bafilomycin A1, a potent and specific inhibitor of V-
H+-ATPases (6), inhibits bone resorption both in vitro
(7) and in vivo (8). However, since bafilomycin is not
selective for any particular type of V-H+-ATPases, when
administered to animals it inhibits all the essential V-
H+-ATPases leading to systemic alteration of cellular
physiology and to unacceptable toxicity (9).
Recently, a novel class of small molecules endowed
with potent osteoclast V-H+-ATPase inhibitory activity
has been discovered (10), whose optimization resulted
in (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-
(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadien-
amide (SB 242784; Figure 1) (11).
The in vitro V-H+-ATPase inhibitory profile of SB
242784 has been reported previously (11). SB 242784 was
a low-nanomolar inhibitor (IC50 = 26.3 nM) of the
bafilomycin-sensitive (vacuolar) Mg2+-ATPase in mem-
brane preparations of osteoclasts obtained from egg-lay-
ing hens. In addition, SB 242784 was a very potent
inhibitor of bone resorption (IC50 = 3.4 nM) in an assay
measuring the collagen fragments released from bone
slices after a 48-hour incubation with human osteoclasts.
In this paper we characterize further the biochemical
and pharmacological actions of SB 242784 and demon-
strate that it is highly selective for the V-H+-ATPase of
human osteoclasts when compared with V-H+-ATPases
from a number of other human tissues. Most impor-
tantly, we show that oral administration of SB 242784
reduces the retinoid-induced hypercalcemia in thy-
roparathyroidectomized (TPTX) rats and prevents the
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increased rate of bone resorption and the consequent
bone loss that is observed in rats after ovariectomy.
Importantly, at fully active therapeutic doses, SB
242784 has no effect on urinary acid excretion. Since
V-H+-ATPase located on the plasma membrane in
kidneys participates in urinary acidification, this
finding confirms in vivo the selectivity of SB 242784
measured in vitro.
Methods
In situ cytochemical Mg-ATPase assay. The cytochemical
assay developed for determining V-ATPase activity in
tissue sections was derived from the method
described by Chayen (12). The basis of the assay is the
use of the phosphate-trapping agent lead ammonium
citrate/acetate (LACA) complex. Free phosphate gen-
erated by endogenous enzymatic hydrolysis of exoge-
nously added ATP (within individual cells of the tis-
sue section) competes with ammonium citrate
moieties and precipitates lead phosphate, which can
be converted to a colored (brown/black) lead sulphide
precipitate with ammonium sulphide.
Fresh, unfixed, 8-m m cryostat sections were preincu-
bated for 15 minutes at 37°C in a 10% solution of
Polypep 5115 in 0.2 M Tris buffer, pH 7.5, to remove free
phosphate. The sections were incubated at 37°C for 10
minutes in reaction medium containing 4 mM ATP, 50
mM MgCl2, and 8 mg/mL LACA in 10% Polypep 5115
in 0.2 M Tris buffer, pH 7.5. All reagents were supplied
by Sigma Chemical Co. (St. Louis, Missouri, USA). The
assay was performed on serial sections containing
increasing concentrations of bafilomycin (0, 0.001–10
nM) or SB 242784 (0, 0.005–50 m M). Serial sections were
also assayed in the presence of 10 nM bafilomycin and
10 nM bafilomycin plus 50 m M SB 242784. Statistical
analysis was done using an unpaired t test.
Reaction product was quantified using a Vickers M85
scanning and integrating microcytophotometer, a
spectrophotometer built around a microscope. This
instrument facilitates the measurement of the amount
of chromophore in individual cells using a disc of light
visible to the operator but not the instrument photo-
multiplier. A spot of light of known wavelength is then
sent through the objective and onto the specimen. This
spot traverses the cell in a raster pattern and then pass-
es on to the photomultiplier. The instrument then
summates all measured absorptions for the area
scanned. The spot takes measurements only within the
area selected by the light disc. Using a filter of known
absorbance, the absolute mean integrated extinction
(MIE) can be determined for each cell. Thirty cells were
measured in triplicate sets of sections of the following:
human and cynomolgus monkey kidney (proximal
cells) and liver (hepatocytes); monkey brain; human
spleen, stomach, heart, and giant cell tumor (rich in
osteoclasts). Randomized measurements were record-
ed blind at distinct sites for each section with the
instrument settings as follows: a mask size suitable for
the specimen, a · 40 objective, and a spot size of 0.5 m m
at a wavelength of 580 nm.
Results are presented as MIE · 100 ± SEM, or
expressed as percentage of control. In all cell types
ATPase activity was substrate and magnesium depend-
ent and linear with time for up to 30 minutes. The
assay omits Na+ or K+ ions, and thus ouabain-sensitive
(0.4 mM) Na+/K+-ATPase activity within tissue sections
was negligible. L-p-bromotetramisole oxalate (0.4 mM;
specific inhibitor of alkaline phosphatase) had no
inhibitory effect on ATPase activity.
Hypercalcemia induced by the retinoid Ro 13-6298 in
TPTX rats
Animals/administration of test compounds. The method
used was similar to that described by Trechsel (13).
Male thyroparathyroidectomized (TPTX) Sprague-
Dawley rats (Charles River, Calco, Italy), weighing
175–200 g, were maintained at 22 ± 1°C, 12-hour
light/dark cycle, fed with a standard diet (Mucedola
No. 4RF21, Settimo Milanese, Milan, Italy) and water
ad libitum. After a week of acclimatization, during
which the animals received 1 m g thyroxin subcuta-
neously every other day, total plasma calcium was
measured and only rats with calcium values less than
1.75 mM were considered TPTX. The TPTX rats were
randomly divided into four groups of eight each and
placed in single cages. Retinoid Ro 13-6298 was syn-
thesized according to the procedure described by
Loeliger (14) and was injected subcutaneously at the
dose of 30 m g/rat in 0.1 mL of polyethylene glycol 300
with 10% ethanol for 3 days to all animals. At the same
time, SB 242784, suspended in 1% methylcellulose,
was administered orally at doses of 2.5, 5, and 10
mg/kg, to groups 1–3 respectively, whereas group 4
received vehicle alone.
Analytical procedures. Blood samples were taken from
the tail vein of all animals before and 4 days after the
first treatment with retinoid plus test compound. Plas-
ma was then obtained by centrifugation (4300 g for 10
minutes), and total calcium was measured by atomic
absorption spectrophotometry (Varian A400; Varian
Inc., Palo Alto, California, USA). Calcium plasma con-
centrations were expressed in millimolar.
Osteoporosis induced by ovariectomy in rats
Animals/administration of test compounds. Three-month-
old female Sprague-Dawley rats (Charles River Italy),
weighing 220–260 g, were maintained at 22 ± 1°C, 12-
hour light/dark cycle, fed with a standard diet
(Mucedola No. 4RF21; Settimo Milanese) and water ad
libitum. After a week of acclimatization, the animals
were randomly divided into five groups of 10 each and
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Figure 1
Chemical structure of SB 242784.
placed in individual metabolic cages to collect 24-hour
urine samples for determination of urine volume, pH
and total acidity, basal contents of pyridinoline (PYD)
and deoxypyridinoline (DPD). During collection, to
avoid urea degradation, urine samples were maintained
frozen. Basal bone mineral density (BMD) of distal
femur metaphysis and lumbar vertebrae (L3–L6, as
total area) were evaluated. Four days later, under pen-
tobarbitone anesthesia (35 mg/kg intravenously), ani-
mals were bilaterally ovariectomized (groups 1–4) or
sham operated (group 5) (15, 16). Immediately after
surgery, animals were treated with vehicle, estrogen, or
SB 242784. Estrogen (group 1) was administered as
slow-release pellets containing 2.5 mg of 17 b -estradiol
(Innovative Research of America, Sarasota, Florida,
USA); each animal was implanted subcutaneously with
one pellet, which was replaced after 3 months. SB
242784 was administered by oral gavage at 5 and 10
mg/kg (groups 2 and 3, respectively), and 1% methocel
vehicle was given orally to both ovariectomized and
sham-operated rats (groups 4 and 5). All treatments
were performed daily for 6 months. Urinary parame-
ters, PYD and DPD determination, and evaluation of
BMD were performed on a monthly basis for 6 months.
Body weight of the animals was recorded throughout
the experimental period.
Analytical procedures
Measurement of BMD. Determinations were performed
using an Hologic QDR 1000 Plus (Hologic, Waltham,
Massachusetts, USA) X-ray bone densitometer, com-
plete with a 0.64-mm collimator, and using software
specifically designed to measure BMD of small animals
in vivo. The BMD values were expressed as grams per
square centimeter.
Measurement of urinary excretion of PYD and DPD cross-
links. According to the method of Eyre (17), 250- m L
urine samples were hydrolyzed with 12 N HCl at 110°C
for 16 hours. Hydrolysates were then diluted with gla-
cial acetic acid and n-butanol and applied to CF1 cel-
lulose columns to extract the analytes. Samples were
eluted with water, evaporated to dryness at 40°C in a
centrifugal evaporator (Univapo 100H; UniEquip, Mar-
tinsried, Munich, Germany), and reconstituted in 250
m L 1% heptafluorobutyric acid. A 50- m L aliquot was
injected into a C18 reverse-phase column (Supelco Inc.,
Bellefonte, Pennsylvania, USA) and, after an isocratic
separation, fluorimetrically detected (250 nm excita-
tion wavelight, 395 nm emission wavelight). The
interassay coefficient of variation was 12.9% for PYD
and 13.1% for DPD. The amounts of PYD and DPD
were expressed as nanomoles per 24 hours.
Measurement of urine total acidity. Free acidity was eval-
uated by titrating urine samples with 0.01 M NaOH at
pH 7.4. NH4+ content was determined by enzymatic bio-
analysis (Urea/Ammonia Kit; Boehringer Mannheim,
Mannheim, Germany). Total acidity of urine was meas-
ured as the sum of free acidity and ammonium content
and is expressed in equivalents per liter (N).
Histomorphometry
All animals received 10 mg/kg of calcein intraperi-
toneally, 13 and 4 days before necropsy. Bone samples
were fixed, stained with Villanueva stain, dehydrated
through increasing concentrations of ethanol, defatted
in acetone, and embedded in methyl methacrylate (Poly-
sciences, Inc., Warrington, Pennsylvania, USA). Longitu-
dinal undecalcified sections (5 m m) collected from three
planes (separated by 100 m m) of the proximal tibia were
cut on a Leica microtome (SM2500S). Histomorphome-
tric analysis was carried out using an Osteomeasure Sys-
tem (OsteoMetrics Inc., Atlanta, Georgia, USA), without
knowledge of group allocation. Measurements were
restricted to a mean tissue area of approximately 8 mm2,
beginning 1 mm below the epiphyseal growth plate. Pri-
mary measurements included area of bone and marrow
(square millimeter), bone area (square millimeter),
perimeter of bone (millimeter), single-labeled perimeter
(sL.PM; millimeter) and double-labeled perimeter
(dL.Pm; millimeter), osteoid perimeter (O.Pm; millime-
ter), and eroded perimeter (Er.Pm; millimeter). Derived
indices included trabecular bone volume (Tb.Ar; per-
centage), trabecular number (Tb.N; number per mil-
limeter), trabecular thickness (Tb.Th; micrometer), tra-
becular separation (Tb.Sp; micrometer), bone formation
rate with bone surface referent (BFR/BS; cubic microm-
eter per square micrometer per year), BFR/BV (bone area
referent; percentage per year), BFR/TV (tissue area refer-
ent; percent per year), mineral apposition rate (MAR;
micrometer per day), and percent of labeled perimeter
(L.Pm; percentage).
Urinary acid excretion in acid-loaded rats
Experimental protocol. Adult female Sprague-Dawley rats
weighing 250 g were divided into six groups of eight
animals each: groups 1–3 (controls) had free access to
tap water; groups 4–6 (acid-loaded rats) had free access
to drinking water containing 280 mM (1.5%) NH4Cl
plus 1% sucrose, for 8 days. All rats were fed with a stan-
dard rodent laboratory diet (Mucedola 4RF21; Settimo
Milanese). The diet contained 1,260 IU/kg vitamin D3,
and estrogen was absent. Volume, pH and total acidity
of urine, and water intake were monitored daily. At day
2, when acid-loaded rats presented a stable acidosis, all
groups were treated orally with vehicle (groups 1 and
4), SB 242784 at 5 mg/kg (groups 2 and 5), and SB
242784 at 10 mg/kg (groups 3 and 6).
Measurements of urine total acidity. Free acidity was
evaluated by titrating urine samples with 0.01 M
NaOH at pH 7.4. NH4+ content was determined by
enzymatic bioanalysis (Boehringer Ammonia Kit).
Total acidity of urine was measured as the sum of free
acidity and ammonium content and is expressed in
equivalents per liter (N).
Measurements of ammonium balance. Ammonium bal-
ance was calculated by dividing the urinary NH4+ out-
put by the daily NH4+ intake, both expressed as mil-
liequivalents per day.
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Statistical analysis
In situ cytochemical Mg2+-ATPase assay and histomorphom-
etry. Statistical analysis was done by an unpaired t test
(two-tailed).
Hypercalcemia induced by the retinoid Ro 13-6298 in TPTX
rats and osteoporosis induced by ovariectomy in rats. Statisti-
cal analysis was performed using RS1/Explore pro-
grams (BBN Software Products, Cambridge, Massa-
chusetts, USA). Data were expressed as the mean plus
or minus standard error for each group. Analysis of all
parameters were based on two-way ANOVA. When sig-
nificant differences were indicated, effects of treat-
ments were compared by a multicompare procedure. A
P value lower than 0.05 was considered significant.
Results
Inhibition of V-H+-ATPase in situ
Selectivity studies. This assay allows the quantitation of
ATPase activity in individual cells in situ and was used to
estimate the relative effects of SB 242784 on V-H+-ATPase
in several human and cynomolgus monkey tissues. As
discussed in Methods, the assay relies on the use of the
phosphate-trapping agent LACA complex, precluding
the use of undecalcified sections of human and monkey
bone. To address this, osteoclast V-H+-ATPase activity was
assayed in multiple sections from six different osteoclas-
tomas. V-ATPase activity was inhibited by bafilomycin in
a dose-dependent manner (Figure 2a). Based on
bafilomycin sensitivity, approximately 25% of the Mg2+-
ATPase activity was V-H+-ATPase in osteoclasts and kid-
ney proximal convoluted (KPC) tubule cells (Figure 2a).
The remaining activity represents microsomal/mito-
chondrial bafilomycin-insensitive Mg2+-ATPase(s).
For each concentration of SB 242784 tested (0–50
m M), serial sections were assayed in the presence of 10
nM bafilomycin (estimated 100% inhibition of V-H+-
ATPase) and 10 nM bafilomycin plus 50 m M SB
242784 (to ascertain whether SB 242784 inhibited a
bafilomycin-insensitive component). Human osteo-
clast Mg2+-ATPase was potently inhibited by SB
242784 (Figure 2b). Based on bafilomycin sensitivity
(estimated maximum inhibition at 10 nM), the
osteoclast V-H+-ATPase was significantly inhibited by
SB 242784 with an estimated IC50 less than 5 nM.
The effects of SB 242784 on V-H+-ATPase activity in
human KPC tubule cells and liver hepatocytes are
also shown in Figure 2b. Kidney and liver cells
demonstrated no concentration-dependent inhibi-
tion up to 5 m M, but demonstrated 40% and 80%
inhibition, respectively, at the maximum concentra-
tion of 50 m M. Comparison between giant cell tumor,
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Figure 2
Effects of SB 242784 on the activity of total Mg2+-ATPase activ-
ity. Results are expressed as MIE · 100 ± SEM. (a) Effect of
bafilomycin-A1 (baf-A1, squares) and SB 242784 (diamonds);
AP < 0.001 versus control (lowest concentration achieved). (b)
Effect of SB242784 on osteoclast Mg2+-ATPase activity, KPC
cells (squares), and liver hepatocytes (triangles). AP < 0.001 ver-
sus control; BP < 0.05 versus control. (c) Additive effects of
bafilomycin and SB 242784 on Mg2+-ATPase activity in human
osteoclasts. AP < 0.001 versus control. (d) Effects of SB 242784
on Mg2+-ATPase activity in human osteoclasts (diamonds),
cynomolgus monkey (CM) KPC cells (open squares), CM
microglial cells (brain, triangles), and CM liver hepatocytes
(closed squares). AP < 0.001, BP < 0.05, CP < 0.02, DP < 0.005,
all versus control.
Figure 3
Effect of SB 242784 on retinoid-induced hypercalcemia in TPTX
rats (n = 8). Open bars, basal value; filled bars, SB 242784; AP <
0.01 versus vehicle.
spleen, and stomach cell types revealed a similar pro-
file of osteoclast selectivity (not shown). Osteoclasts
demonstrating no bafilomycin-sensitive ATPase
activity were unaffected by SB 242784 (not shown).
In all cell types, SB 242784 had no effect on
bafilomycin-insensitive ATPase activity and therefore
no effect on other Mg2+-ATPases (osteoclast V-
ATPase shown as representative; Figure 2c).
SB 242784 inhibited V-H+-ATPase in monkey KPC
tubule cells and brain microglial cells at an IC50 of
approximately 5 m M (Figure 2d). SB 242784 had no
effect on V-H+-ATPase activity in cynomolgus monkey
liver hepatocytes, brain granular cells (Figure 2d), or
liver endothelial cells (not shown). In all cell types, SB
242784 had no effect on bafilomycin-insensitive ATPase
activity (not shown).
To characterize further the selectivity of action of this
compound against other enzymes that are known to be
involved in the process of bone resorption, SB 242784
was tested against a number of MMPs and cathepsins.
Only very low inhibitory activity was observed, with an
IC50 of 5 m M for MMP-9 and human cathepsin S. No
activity (IC50 > 10 m M) was displayed for MMP-2,
human and rat cathepsin K, or human cathepsin L
(data not shown).
Effect of SB 242784 on retinoid-induced
hypercalcemia in TPTX rats
It is well-known that excess vitamin A leads to an
increase of osteoclastic bone resorption and of the
number of osteoclasts. Ro 13-6298 is one of the most
potent retinoids known, and it induces a stimulation
of bone resorption in the TPTX rat. The changes in
bone resorption can be monitored by measuring plas-
ma calcium levels (14).
In our experiments subcutaneous injections of 30
m g/rat/d of Ro 13-6298 for 3 days in control TPTX rats
caused a significant increase in plasma calcium levels
from 1.51 ± 0.16 to 2.55 ± 0.07 mM (P < 0.01). Oral
administration of 2.5, 5, and 10 mg/kg of SB 242784
caused dose-related inhibition of retinoid-induced
hypercalcemia of 20% (not significant), 54% (not sig-
nificant), and 128% (P < 0.01), respectively (Figure 3).
Effect of SB 242784 in ovariectomized rats
In a previous experiment performed in adult (8-month-
old) ovariectomized (OVX) rats for 3 months (18), SB
242784 caused statistically significant prevention of
the decrease of BMD at the orally administered dose of
10 mg/kg/d, but not at the lower doses of 1 or 3
mg/kg/d. Therefore, in this 6-month experiment, the
doses of 5 and 10 mg/kg/d of SB 242784, given by
mouth, were chosen for the treatment of OVX rats.
Body weight gain in all groups was monitored
throughout the whole experimental period to obtain
an indication of possible overt toxic effects of SB
242784. As may be observed in Figure 4, where the body
weight of animals at the end of the 6-month experi-
mental period is reported, only estrogen but not SB
242784 treatment caused a statistically significant
decrease of weight gain.
BMD of distal femur metaphysis. Assessment of BMD by
dual-photon absorptiometry (DEXA) clearly showed
that ovariectomy induced a marked, continuous, and
significant decrease in femur BMD between the first
and the sixth month after surgery (Figure 5a). As
expected, the reference compound 17 b -estradiol,
administered as 2.5-mg pellets implanted subcuta-
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Figure 4
Effect of estrogen (E2) and SB 242784 on body weight of OVX rats
at the end of the 6-month treatment. AP < 0.01 versus OVX-vehicle.
Figure 5
Effect of SB 242784 on BMD of distal femur metaphysis (a) and lum-
bar vertebrae L3-L4 (b) in OVX rats, n = 10. Filled diamonds, sham-
operated rats treated with vehicle; open circles, estradiol; open
squares, SB 242784 5 mg/kg; open triangles, SB 242784 10 mg/kg;
closed squares, OVX-vehicle. All points were statistically different
from OVX-vehicle at P < 0.01, except when otherwise indicated: AP <
0.05. NS, not statistically different from OVX-vehicle.
neously, caused a significant protective effect on BMD
at all the time points assessed. Similarly, SB 242784 at
the higher dose of 10 mg/kg/d fully prevented the
decrease of BMD throughout the experimental period.
At the lower dose of 5 mg/kg, SB 242784 maintained a
BMD of the femur metaphysis slightly higher than in
vehicle-treated OVX rats for all the 6 months. This dif-
ference, however, did not reach the statistical signifi-
cance at any time point.
BMD of lumbar vertebrae (L3–L6). Contrary to what
occurred in the femoral metaphysis, the effect of
ovariectomy in these growing animals was to prevent
the age-related increase of BMD of lumbar vertebrae
observed in sham-operated rats. OVX animals treated
with estradiol or 10 mg/kg SB 242784 showed the same
increase of bone density as observed in the sham-oper-
ated group during the whole experimental period (Fig-
ure 5b). Also the lower dose of 5 mg/kg of SB 242784
caused an increase of spine BMD that was statistically
significant at months 5 and 6.
Total urinary PYD and DPD. In comparison with sham-
operated animals, ovariectomy caused significant
increases (P < 0.01) in total urinary levels of PYD at
month 1 and of DPD at months 1 and 2 after surgery,
with a peak effect at the first month (Figure 6). These
increases were completely and significantly (P < 0.01)
prevented by estradiol administration. SB 242784, at 5
and 10 mg/kg/d, fully and significantly (P < 0.01) inhib-
ited DPD increase ovariectomy induced at months 1
and 2 after surgery; at the highest dose of 10 mg/kg,
effect was also observed at month 3. Urinary PYD levels
were not significantly modified by this compound.
Urine volume, pH, and total acidity. In comparison with
sham-operated animals, OVX rats, treated with vehicle
or SB 242784, did not show any differences in urine vol-
ume, pH, and total acidity at all time points. Conversely,
estradiol induced significant increases (P < 0.01) in urine
volume from the second to the sixth month and in total
acidity at months 2 and 3 (data not shown).
Histomorphometry. The effects of OVX, estradiol, and SB
242784 on cancellous bone volume and architecture at
the proximal tibia are shown in Figure 7, a–d. Trabecu-
lar number was significantly lower (47%) in OVX rats rel-
ative to sham controls (Figure 7a), resulting in a signifi-
cant decrease (50%) in trabecular area (Figure 7b).
However, there was no effect of OVX on trabecular thick-
ness (not shown), and the apparent increase (58%) in tra-
becular spacing did not reach significance. The OVX-
induced loss in trabecular number and percentage of
trabecular area was prevented by estradiol and SB
242784 at the higher dose (i.e., not significantly differ-
ent from sham controls; Figure 7, a and b). At the lower
dose of 5 mg/kg, SB 242784 had no effect on any param-
eter. Trabecular spacing was also significantly reduced in
the rats treated with estradiol (74%; P < 0.05 versus OVX)
and SB 242784 at 10 mg/kg (84%; P < 0.03 versus OVX)
relative to the sham group.
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Figure 6
Effect of SB 242784 on total urinary excretion of PYD (a) and DPD
(b) cross-links in OVX rats, n = 10. Open bars, pre-OVX basal value;
filled bars, 1 month; dark-gray bars, 2 months; light-gray bars, 3
months. AP < 0.05; BP < 0.01 versus OVX-vehicle.
Figure 7
Effects of SB 242784 on histomorphometric parameters in OVX rats
(n = 10). Results are presented as mean ± SEM. (a) Trabecular bone
number. AP < 0.005 versus sham, BP < 0.0075 versus OVX, CP < 0.0002
versus OVX. NS, not significantly different from OVX. (b) Percentage
of trabecular area. AP < 0.004 OVX versus sham, and Est (estradiol)
versus OVX, CP < 0.0003 versus OVX. NS, not significantly different
from OVX. (c) Percentage of eroded perimeter; NS (OVX vs. sham and
SB 242784-5 vs. OVX). BP < 0.0383, Est versus OVX, and P < 0.0518,
SB 242784 versus OVX. (d) Percentage of osteoid perimeter.
Percentage of eroded perimeter (Figure 7c) was 133%
higher in the OVX group relative to sham and was nor-
malized (equivalent to sham) by both estradiol (67%
lower) and SB 242784 at 10 mg/kg (62% lower).
Although overall bone turnover is generally increased
in OVX-induced bone loss (19, 20), in this long-term
study bone formation rates (BFR/BV,TV, BS) were low
and equivalent in the OVX and sham groups (not
shown). BFR/BV and BFR/TV were 70% (P < 0.04) and
72% (P < 0.04) lower in the SB 242784 at 10 mg/kg
group, respectively, relative to sham (but not signifi-
cantly different to OVX). The mineral apposition rate
was comparable in all groups. Percentage of osteoid
perimeter was comparable between OVX and sham ani-
mals and not affected (although data were highly vari-
able) by estradiol or SB 242784 (Figure 7d).
In summary, bone resorption (and overall bone remod-
eling) was significantly decreased by SB 242784 at 10
mg/kg, with a significant net gain in bone volume. Fig-
ure 8 shows photomicrographs of trabecular bone area in
the proximal tibia of sham-operated, OVX and OVX ani-
mals treated with SB 242784 at 10 mg/kg for 6 months.
Effects of SB 242784 in acid-loaded rats
Treatment with vehicle or SB 242784, at 5 or 10 mg/kg,
administered by mouth, had no effect on urine pH
(data not shown) and total acid concentration (Figure
9) in both control and acid-loaded animals. In addition,
the same treatments in acid-loaded animals caused no
significant change of ammonium balance, i.e., the ratio
between the amount of ammonium excreted in urine
and the amount of ammonium taken with drinking
water (Figure 10). Ammonium intake with food
accounts for the values greater than 1 for this ratio.
Discussion
Acidification of the resorbing compartment is one of
the most important features of osteoclast biological
activity in the process of bone resorption: the acidic
environment is absolutely required for the degradation
of both inorganic and organic components of bone (3).
The lowering of pH in the bone-resorbing compart-
ment is accomplished by a high concentration of vac-
uolar-type proton pumps (V-H+-ATPases) on the apical
pole of the cell (ruffled border).
It has been shown that expression of the proton chan-
nel part of V-H+-ATPase is stimulated in resorbing osteo-
clasts (21) and that antisense RNA and DNA molecules
targeted against two subunits of the V-H+-ATPase do
indeed inhibit bone resorption by rat osteoclasts (22).
This enzyme is therefore a major potential target for
reducing osteoclast activity and, consequently, for design-
ing novel agents useful for the treatment of osteoporosis.
Proton-translocating V-H+-ATPases (5, 23) are ubiq-
uitous components of eukaryotic organisms and are
the major electrogenic pumps of vacuolar membranes.
The V-H+-ATPases pump protons from the cytoplasm
to the lumen using the energy released by ATP hydrol-
ysis. The electrical potential difference created across
the membrane is used to drive the movement of ions
and solutes into the vacuole. Given the ubiquitous
nature of vacuolar proton pumps, therapeutically use-
ful V-H+-ATPase inhibitors would need to be able to
discriminate between the osteoclast enzyme and the
other essential V-H+-ATPases.
Although sequence differences between the subunits of
V-H+-ATPases of different origins have been reported, the
existence of biochemically distinct isoforms of the enzyme
have not been demonstrated until very recently. Previous-
ly, discordant evidence has appeared in the literature,
either supporting or rejecting the existence of an isoform
of enzyme uniquely expressed in the plasma membrane of
the osteoclasts. Whereas osteoclasts do express the ubiq-
uitous subunits B2 (24, 25) and C-E (26), “osteoclast-spe-
cific” 67-kD subunit A (27, 28) and 116-kD (29) subunits
were described, which, however, were subsequently shown
to be ubiquitously expressed in human tissues (30, 31).
Also, the “peculiar sensitivity” of chicken osteoclast V-
ATPase to vanadate (32) and to nitrate (33) has not been
confirmed by independent investigators in either chicken
(4, 34, 35) or mammalian (36) osteoclasts.
Very recently, however, the existence of a specific
osteoclast 116-kD (OC-116 kD) subunit has been con-
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Figure 8
Photomicrographs of trabecular bone area in the proximal tibia of
sham-operated (a), OVX (b), and OVX animals treated with estro-
gen (c) and SB 242784 10 mg/kg (d) for 6 months.
firmed by in situ hybridization and sequence analysis
(37). Knockout mice with a null mutation in the ATP6i
gene, coding for the OC-116 kD subunit were growth
retarded and developed severe osteopetrosis (38). Het-
erozygous animals appeared normal. Histological
analysis of the OC-116 kD–/– mice revealed long-bone
abnormalities manifested as the absence of marrow
cavities and expanded growth plates with an extended
zone of calcified cartilage. Enzyme histochemical
analysis showed that OC-116 kD–/– mice have a normal
number of osteoclasts that attach to bone but do not
form resorption lacunae. Importantly, OC-116 kD–/–
mice had normal acid-base balance of blood and urine
and functional intracellular acidification, illustrating
that OC-116 kD-null mutation is unlikely to affect V-
ATPase of lysosomes/endosomes and kidney tubule
cells. From all these data it appears that the osteoclast
116 kD is structurally and functionally different from
the corresponding subunits in other V-ATPases.
Starting from bafilomycin A1, a potent inhibitor of all
the V-H+-ATPases, we were able to design a novel class of
compounds with strong V-H+-ATPase–inhibitory activi-
ty and possessing a clear-cut selectivity for the osteoclast
enzyme. The most representative compound of the class
is SB 242784, whose in vitro V-H+-ATPase inhibitory pro-
file has been reported previously (11). SB 242784 is a low-
nanomolar inhibitor (IC50 = 26.3 nM) of the bafilomycin-
sensitive (vacuolar) Mg2+-ATPase in membrane
preparations of osteoclast obtained from egg-laying hens.
In addition, SB 242784 was a very potent inhibitor of
bone resorption (IC50 = 3.4 nM) in an assay measuring the
collagen fragments released from bone slices after 48-
hour incubation with human osteoclasts. Although there
is no reason to believe that the expression of any of the
ATPase subunits is affected by SB 242784, this possibili-
ty has not been ruled out experimentally.
In this paper we have further characterized this com-
pound with regard to its selectivity for the human osteo-
clast enzyme when compared with other V-H+-ATPases in
different human tissues. Using an in situ cytochemical
assay capable of measuring ATPase activity in single cells,
it was possible to demonstrate that SB 242784 has greater
than 1,000-fold selectivity for the osteoclast V-H+-ATPase
compared with the enzyme measured in kidney, liver,
spleen, stomach, brain, or endothelial cells. It has no
effect on other cellular ATPases. The molecular mecha-
nism by which SB 242784 exerts its selectivity is poorly
understood. The lipophilic nature of this compound
might suggest an interaction with one or more compo-
nents of the integral membrane domain, for example, the
116-kD subunit for which different isoforms have been
identified in human (29) and rabbit osteoclasts (37, 39)
or the 16-kD proteolipid, whose sequence in human
osteoclast is still unknown and for which several genes
have been identified in the human genome (40). In any
case specific studies on the interaction of SB 242784 with
the enzyme subunits are required to precisely identify the
protein target of this class of inhibitors.
The observed in vitro antiresorptive activity of SB
242784 is unlikely to be due to its action on different
enzymes that are known to be involved in the bone-
resorption process; this is supported by its very low or
no inhibitory activity against a series of MMPs or
cathepsins that were inhibited by SB 242784 only at
concentrations of 5 m M or higher.
When tested in animal models of bone resorption in
vivo, SB 242784 inhibited bone resorption in both
acute and chronic models in the rat. Retinoid Ro 13-
6298 induced a stimulation of bone resorption with a
consequent increase in calcium plasma levels in TPTX
rats (14). In this acute model, oral administration of SB
242784 for 3 days inhibited, in a dose-related way, the
retinoid-induced hypercalcemia, with complete pre-
vention at the higher dose of 10 mg/kg.
Bone loss induced by ovariectomy in rats and post-
menopausal bone loss present similar characteristics,
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Figure 9
Effect of SB 242784 on urinary total acidity (N) in rats drinking tap
water (a) or 1.5% NH4Cl plus 1% sucrose (b). No statistically signif-
icant difference was observed before (open bars) or 24 hours after
(filled bars) the treatment.
Figure 10
Effect of SB 242784 on the ratio between ammonium excreted in
urine and ammonium taken in with drinking water in acid-loaded rats.
Open bars, before treatment; filled bars, 24 hours after treatment.
such as increased rate of bone turnover with resorption
exceeding formation, an initial rapid phase of bone loss
followed by a slower phase, greater loss of cancellous
than cortical bone, decreased intestinal absorption of
calcium, and similar skeletal response to therapy with
estrogen. All these similarities provide strong evidence
that the OVX rat bone-loss model is suitable for study-
ing problems that are relevant to postmenopausal bone
loss (41). In this animal model chronic treatment for 6
months with 10 mg/kg/d of SB 242784 by mouth fully
prevented the decrease in BMD induced by ovariecto-
my in the femur and lumbar spine throughout the
treatment period. The decrease of BMD in the lumbar
spine was significantly reduced also with the lower dose
of 5 mg/kg/d of this compound administered orally at
months 5 and 6.
Bone constitutes the major pool of PYD and DPD
cross-links. Although quantities of DPD have been
detected in soft tissues such as the aorta and ligaments
(42), the turnover of collagen in these tissues is very
low, and thus urinary DPD can be considered to be a
specific marker for bone-collagen degradation (43, 44).
Two studies have demonstrated the close association
between urinary cross-link excretion and the rate of
bone resorption, as determined by radioisotopic and
histomorphometric measurements. It is generally
accepted that these cross-links, as measured in the
urine, reflect bone resorption (45). Urinary DPD levels
were significantly reduced with both doses of SB
242784 at months 1 and 2, and, at the higher dose of
10 mg/kg/d, this effect was evident also at month 3.
Contrary to estrogen and sham groups, no significant
modification in PYD levels were observed in SB
242784-treated groups. These biochemical indices were
consistent with a partial suppression of the increase in
bone turnover that follows ovariectomy.
Static and dynamic histomorphometry of the proxi-
mal tibia confirmed that SB 242784, at the higher dose
of 10 mg/kg/d, prevented the OVX-induced loss in tra-
becular number and area. The antiresorptive mecha-
nism of action of SB 242784 was confirmed by the sig-
nificant reduction in the extent of eroded surfaces
(percentage of Er.Pm) and bone turnover (BFR/BV).
The 6-month treatment with 5 or 10 mg/kg/d of SB
242784 caused no overt toxic effect in OVX rats. They
behaved normally during the whole experimental peri-
od, and their weight at the end of treatment was not
statistically different from that of OVX rats treated
with vehicle. As expected, estrogen replacement signif-
icantly decreased body weight. However, it should be
noted that other V-H+-ATPase–dependent processes
were not explicitly studied, so complete specificity can-
not be claimed.
During this study, the possible effect of the treat-
ment on renal V-H+-ATPase was also monitored by
measuring the volume, pH, and total acidity of the
urine. It is known, in fact, that a V-H+-ATPase in the
intercalated cells of convoluted tubules is responsible
for urinary acidification and bicarbonate reabsorption.
As predicted by in vitro data, no effect of SB 242784
was observed in the treated animals when compared
with controls, confirming, also in vivo, its selectivity
for the osteoclast enzyme.
To further confirm the lack of effect of SB 242784
on urinary acidification by kidney V-H+-ATPase, an
acid-loaded model was set up that could better detect
any possible effect. It is known that response to acid
loading in rats involves transport of large amounts of
V-H+-ATPase from the cytoplasmic vesicles to plasma
membranes (46), where it is crucial for the mainte-
nance of urinary pH.
Urinary acid output increased by about 10-fold in
animals drinking a solution containing 1.5% ammoni-
um chloride and 1% sucrose (Figure 9b), as compared
with animals drinking water (Figure 9a). However,
treatment with 5 or 10 mg/kg/d of SB 242784 did not
affect total acid output (Figure 9) or urine pH (data not
shown). Also, the animals treated with SB 242784 were
able to excrete all the ammonium load in a manner
similar to vehicle-treated rats (Figure 10).
In summary, all endpoints measured demonstrated
outstanding efficacy of SB 242784 in the prevention of
ovariectomy-induced bone loss, including BMD, bio-
chemical markers of bone resorption, and histomor-
phometry. There were no overt adverse effects of
administration of SB 242784 to rats for 6 months,
including a lack of effect on kidney function or urine
acidification. These studies clearly define the osteoclast
V-ATPase as an excellent target for antiresorptive ther-
apy for osteopenic disorders such as osteoporosis.
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